Drug General Information |
Drug ID |
D0G4AJ
|
Former ID |
DIB001165
|
Drug Name |
AGN-208397
|
Indication |
Retinal venous occlusion [ICD10:H34.8]
|
Phase 1/2 |
[1]
|
Company |
Allergan Inc
|
Target and Pathway |
Target(s) |
Receptor protein-tyrosine kinase erbB-2 |
Target Info |
Inhibitor |
[2]
|
KEGG Pathway
|
ErbB signaling pathway
|
Calcium signaling pathway
|
HIF-1 signaling pathway
|
Focal adhesion
|
Adherens junction
|
Pathways in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancer
|
Pancreatic cancer
|
Endometrial cancer
|
Prostate cancer
|
Bladder cancer
|
Non-small cell lung cancer
|
Central carbon metabolism in cancer
|
NetPath Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
Cadherin signaling pathway
|
EGF receptor signaling pathway
|
Pathway Interaction Database
|
ErbB4 signaling events
|
ErbB2/ErbB3 signaling events
|
ErbB receptor signaling network
|
a6b1 and a6b4 Integrin signaling
|
Validated targets of C-MYC transcriptional repression
|
PathWhiz Pathway
|
Phosphatidylinositol Phosphate Metabolism
|
Reactome
|
SHC1 events in ERBB2 signaling
|
PLCG1 events in ERBB2 signaling
|
PIP3 activates AKT signaling
|
GRB2 events in ERBB2 signaling
|
PI3K events in ERBB2 signaling
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
Sema4D induced cell migration and growth-cone collapse
|
RAF/MAP kinase cascade
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
ErbB Signaling Pathway
|
EGF/EGFR Signaling Pathway
|
Focal Adhesion
|
Extracellular vesicle-mediated signaling in recipient cells
|
Bladder Cancer
|
Signaling by ERBB2
|
Integrated Pancreatic Cancer Pathway
|
Signaling Pathways in Glioblastoma
|
Leptin signaling pathway
|
miR-targeted genes in muscle cell - TarBase
|
Semaphorin interactions
|
References |
REF 1 | ClinicalTrials.gov (NCT01027650) Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO). U.S. National Institutes of Health. |
---|
REF 2 | New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2. |